Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:candy
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:phenobarbital
|
| gptkbp:approves |
1912
|
| gptkbp:brand |
Luminal
|
| gptkbp:composed_of |
from malonic acid
from diethyl malonate from urea |
| gptkbp:contraindication |
porphyria
severe liver disease severe respiratory disease |
| gptkbp:discontinued |
in some countries
|
| gptkbp:duration |
long-term use possible
short-term use recommended for insomnia |
| https://www.w3.org/2000/01/rdf-schema#label |
Phenobarbital Sodium
|
| gptkbp:ingredients |
C12 H12 N2 O3 S
|
| gptkbp:interacts_with |
with alcohol
with benzodiazepines with opioids |
| gptkbp:is_atype_of |
N03 A A02
|
| gptkbp:is_available_on |
gptkb:tablet
injection elixir |
| gptkbp:is_monitored_by |
liver function tests recommended
serum drug levels recommended |
| gptkbp:is_used_for |
anxiety treatment
seizure control insomnia treatment |
| gptkbp:legal_issue |
Prescription only
|
| gptkbp:lifespan |
about 80 hours
|
| gptkbp:manager |
oral
intravenous |
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
highly protein-bound
GABA receptor agonist |
| gptkbp:products |
gptkb:phenobarbital
pentobarbital secobarbital amobarbital butalbital |
| gptkbp:side_effect |
dizziness
nausea drowsiness respiratory depression |
| gptkbp:symptoms |
anxiety
seizures insomnia tremors delirium |
| gptkbp:type_of |
57-30-1
|